Spotlight On... Takeda bails on obesity med Contrave, spelling trouble for maker Orexigen; Vectura inks all-stock pact for SkyePharma; Allergan launches Vraylar in the U.S.; and more...

Amid underperforming sales and an expensive outcomes trial tab, Takeda is walking away from its marketing pact with Orexigen ($OREX) for obesity therapy Contrave. Now, it'll be up to Orexigen to compete in the U.S. without the Japanese pharma's 900 reps, who helped it grab a leading slice of the pie despite third-to-market entry. But in the meantime, Orexigen is also on the hook for a cardiovascular outcomes trial that could cost up to $250 million--a tall order for the California drugmaker, which netted just $53 million in Contrave sales last year. More from FiercePharmaMarketing

@FiercePharma: Activist Ackman vows to intervene after disastrous day at Valeant. Story | Follow @FiercePharma

@EricPFierce: ICYMI: Vertex, committed to continuous manufacturing, has Hovione build plant to complement the one it already has. Article | Follow @EricPFierce

@CarlyHFierce: I've wasted a solid part of my morning just staring at pg. 42 in disbelief. More | Follow @CarlyHFierce

> Respiratory drugmaker Vectura has agreed to buy SkyePharma in an all-stock deal that values the drugmaker at $621.9 million. Report

> Allergan ($AGN) has launched antipsychotic Vraylar in the U.S. Release

> Indian officials are working on a statutory code of conduct for pharmaceutical marketing after reports of unethical practices. Report

> Novartis' ($NVS) Entresto was cleared for marketing in Singapore, the latest country to approve the heart failure med. Report

> The journal Vaccine has yanked a "seriously flawed" and "unjustified" study that purported to find new side effects to Merck's ($MRK) HPV shot Gardasil. Report

> Bayer is setting up an East Coast innovation hub in Cambridge, MA, joining a wide array of biopharma companies looking to take advantage of the institutions and expertise there. Report

Medical Device News

@FierceMedDev: Dexcom integrates its latest CGM into the Apple Watch. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: FDA panelists to focus on use of Abbott's Absorb in small vessels during deliberations. More | Follow @VarunSaxena2

@EmilyWFierce: Good news, hep C drugmakers: VA stops rationing your pricey treatments. FiercePharmaMarketing story | Follow @EmilyWFierce

> AliveCor discloses EKG band for Apple Watch, upgrades existing a-fib app. Report

Biotech News

@FierceBiotech: MIT team demonstrates potential of cancer combo for kinase inhibitors in mice. More from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: Biotech Lesson: Be overtly transparent. If you're hiding something bad, you're asking for it. , , etc. | Follow @JohnCFierce

> Bayer plots a dealmaking hub in the biotech boomtown of Cambridge, MA. Report

> Vectura lands $621M merger deal with SkyePharma. Story

> Takeda and Frazier back a $41M round for a new urology biotech. Article

Pharma Marketing News

> GlaxoSmithKline's nicotine franchise pairs up with smoking cessation app. Report

> Good news, hep C drugmakers: VA stops rationing your pricey treatments. More

> Getting serious about digital: Takeda walks the walk with its digital accelerator model. Story

> Takeda dumps weight loss med Contrave, leaving Orexigen in the lurch. Article

Biotech Research News

> Novartis-allied scientist at Penn creates a new CAR-T model for solid tumors. More

> HDAC/PI3K inhibitors could treat common childhood cancer. Report

> MIT team demonstrates potential of cancer combo for kinase inhibitors in mice. Story

> New insights into Parkinson's disease. Item

> HIV drug increases therapeutic window for skin cancer by slowing drug resistance. Article

Vaccines News

> Journal walks back 'seriously flawed' study critical of Merck's Gardasil. More

> Analyst: Mitsubishi Tanabe's tobacco-based flu jab could have 'significant impact' on market. Story

> Health agencies inform on Zika vaccine timeline. Report

> Valneva scores $42M supply contract with DOD. News

> Duke, NIAID track HIV evolution with eyes on creating a vaccine. Article

And Finally... Some new genetic tests are designed to show how different people metabolize different drugs, but opinions about their utility vary. Report

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.